Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis.

RATIONALE Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease that likely includes clinically relevant subgroups. OBJECTIVES To identify subgroups of COPD in ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) subjects using cluster analysis and to assess clinically meaningful outcomes of the clusters during 3 years of longitudinal follow-up. METHODS Factor analysis was used to reduce 41 variables determined at recruitment in 2,164 patients with COPD to 13 main factors, and the variables with the highest loading were used for cluster analysis. Clusters were evaluated for their relationship with clinically meaningful outcomes during 3 years of follow-up. The relationships among clinical parameters were evaluated within clusters. MEASUREMENTS AND MAIN RESULTS Five subgroups were distinguished using cross-sectional clinical features. These groups differed regarding outcomes. Cluster A included patients with milder disease and had fewer deaths and hospitalizations. Cluster B had less systemic inflammation at baseline but had notable changes in health status and emphysema extent. Cluster C had many comorbidities, evidence of systemic inflammation, and the highest mortality. Cluster D had low FEV1, severe emphysema, and the highest exacerbation and COPD hospitalization rate. Cluster E was intermediate for most variables and may represent a mixed group that includes further clusters. The relationships among clinical variables within clusters differed from that in the entire COPD population. CONCLUSIONS Cluster analysis using baseline data in ECLIPSE identified five COPD subgroups that differ in outcomes and inflammatory biomarkers and show different relationships between clinical parameters, suggesting the clusters represent clinically and biologically different subtypes of COPD.

[1]  Edwin K Silverman,et al.  Chronic obstructive pulmonary disease phenotypes: the future of COPD. , 2010, American journal of respiratory and critical care medicine.

[2]  S. Sahn,et al.  Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. , 2011, American journal of respiratory and critical care medicine.

[3]  L. Edwards,et al.  Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. , 2013, American journal of respiratory and critical care medicine.

[4]  Gianna Camiciottoli,et al.  Identification of a predominant COPD phenotype in clinical practice. , 2008, Respiratory medicine.

[5]  D. Caillaud,et al.  Clinical COPD phenotypes identified by cluster analysis: validation with mortality , 2012, European Respiratory Journal.

[6]  T. W. van der Mark,et al.  Relation of lung function, maximal inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease. , 1994, Thorax.

[7]  Courtney Crim,et al.  Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.

[8]  M. Krane,et al.  Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis , 2003, European Respiratory Journal.

[9]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[10]  D. Sin,et al.  The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[11]  K. Wasserman,et al.  The body weight-walking distance product as related to lung function, anaerobic threshold and peak VO2 in COPD patients. , 2001, Respiratory medicine.

[12]  W. MacNee,et al.  Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) , 2008, European Respiratory Journal.

[13]  Thierry Troosters,et al.  Two Distinct Chronic Obstructive Pulmonary Disease (COPD) Phenotypes Are Associated with High Risk of Mortality , 2012, PloS one.

[14]  Josep Roca,et al.  Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes , 2010, Thorax.

[15]  D. Caillaud,et al.  Clinical COPD phenotypes: a novel approach using principal component and cluster analyses , 2010, European Respiratory Journal.

[16]  Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials , 2012, Circulation.

[17]  N. Laird,et al.  Cluster analysis in severe emphysema subjects using phenotype and genotype data: an exploratory investigation , 2010, Respiratory research.

[18]  J. Casillas,et al.  DETERMINING THE MINIMAL CLINICALLY IMPORTANT 1 DIFFERENCE FOR THE SIX-MINUTE WALK TEST AND THE 2002 METER FAST WALK TEST DURING CARDIAC REHABILITATION 3 PROGRAM IN CORONARY ARTERY DISEASE PATIENTS AFTER 4 ACUTE CORONARY SYNDROME , 2017 .

[19]  Yasutaka Nakano,et al.  Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[20]  S. Rennard,et al.  Chronic Bronchitis and Emphysema , 2010 .

[21]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[22]  B. Everitt,et al.  Cluster Analysis: Everitt/Cluster Analysis , 2011 .

[23]  Martijn A Spruit,et al.  Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[24]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[25]  S. Horvath,et al.  Unsupervised Learning With Random Forest Predictors , 2006 .

[26]  L. Edwards,et al.  COPD association and repeatability of blood biomarkers in the ECLIPSE cohort , 2011, Respiratory research.

[27]  P. Jones,et al.  Issues concerning health-related quality of life in COPD. , 1995, Chest.

[28]  Courtney Crim,et al.  The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. , 2013, The Lancet. Respiratory medicine.

[29]  A. Holland,et al.  The return of the minimum clinically important difference for 6-minute-walk distance in chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[30]  Stephanie A. Santorico,et al.  Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema , 2014, Thorax.